Skip to main content
Premium Trial:

Request an Annual Quote

MRM Proteomics, PROOF Team on Chronic Disease Dx

NEW YORK (GenomeWeb News) – The Centre of Excellence for the Prevention of Organ Failure (PROOF) and MRM Proteomics announced today that they will partner on proteomic-based diagnostic tests for patients with chronic organ diseases.

The partners' goal is to develop blood-based tests that can help clinicians more effectively manage patients with heart, lung, and kidney diseases.

The non-profit PROOF Centre will apply its computational pipeline to guide the experimental design and data quality control and analysis needed for identifying protein signatures that can be used with other molecular signals to indicate heart, lung, and kidney disease.

MRM provides protein quantitation and proteomic services to biotech and diagnostic firms using multiple reaction monitoring-mass spectrometry technology. The firm's PeptiQuant MRM assays enable absolute quantitation of hundreds of proteins at a time from a single drop of blood.

"Our organizations’ offerings are clearly complementary in the field of protein biomarker discovery and validation," Andrew Munk, president and CEO of MRM, said in a statement. "The discovery, validation and implementation of biosignatures are complex processes. Partnering with the PROOF Centre will provide our customers with access to the PROOF Centre’s internationally recognized computational tools and capabilities to optimize the design and analysis of their mass spec based proteomic biomarker studies.”

Financial and other terms of the alliance were not disclosed.

Both the PROOF Centre and MRM are based in Vancouver, British Columbia.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.